Leading A tRNA Startup With Alltrna's Michelle Werner

We love to hear from our listeners. Send us a message. On this week"s episode, Michelle Werner, CEO at Alltrna, talks transfer RNA (tRNA) therapy with host Ben Comer and guest co-host Anna Rose Welch, editorial and community director at Advancing RNA. Werner explains why a single engineered tRNA therapy has the potential to treat "hundreds, if not thousands," of rare genetic diseases, and how her own child"s rare disease diagnosis shaped her career and approach to drug development. Werner also discusses Alltrna"s use of AI and machine learning for drug optimization, the company"s planned use of basket trials, and more.    This episode is brought to you by Avantor. For more information, visit avantorsciences.com Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/